Dr. Jens M. Scherpe, M.A. (Cantab), MJur (Oxon)
The Legal Status of Transsexual and Transgender Persons is the result of an international research project, including not only national reports from 14 European and non-European jurisdictions but also two chapters that look at legal sex/gender changes from a Christian perspective and one chapter from a medical-psychological perspective. The final comparative chapter compares and contrasts the different approaches and requirements and makes recommendations for best practice and law reform.
4 Sep, 2017
4 Sep, 2017
HKU Legal Scholarship Blog
29 Aug, 2017
5 Jun, 2017
Also see Ming Pao 簡尚恆：胎兒的特殊法律地位
Daisy Cheung 張天目
22 May, 2017
16 Apr, 2017
14 Apr, 2017
12 Apr, 2017
South China Morning Post
9 Apr, 2017
9 Apr, 2017
South China Morning Post
Dr Yanhong Jessika Hu
7 Dec, 2017
On 9-10 November, a two-day conference on “Tackling Antimicrobial Resistance (AMR): Meeting the Global Challenge of AMR” was organized by the University of Hong Kong (HKU) Centre for Medical Ethics and Law in collaboration with the HKU School of Public Health. Yanhong Jessika Hu reports from Hong Kong. This conference included four sessions: The Challenge, Emergent Threats - The Experience, The Community Context, and Making It Work. The meeting featured a diverse interdisciplinary group of local and international experts who contributed to the discussion, including lawyers, policy makers, physicians, microbiologists, basic scientists, animal health scientists, community intervention specialists, pharmaceutical association representatives and epidemiologists. The Hong Kong Secretary for Food and Health of the Government of the Hong Kong Special Administrative Region, Professor Sophia Chan, gave the opening remarks, and described how the Hong Kong government of Hong Kong has been working together with international experts to launch the Hong Kong Strategy and Action Plan on Antimicrobial Resistance (2017-2022), which was announced in July 2017. Professor Chan commented that Hong Kong +is uniquely positioned to implement a One Health approach to AMR because food, agriculture and health are all organised under her policy purview.
30 Sep, 2017
On 25-26 August 2017, the Centre for Medical Ethics and Law (CMEL) of the University of Hong Kong, in collaboration with the Centre of Law, Medicine and Life Sciences of the University of Cambridge, Ethox Centre of the University of Oxford and the Hong Kong College of Psychiatrists, hosted a two-day conference on the topic of compulsory mental health treatment in Hong Kong and the way forward. Below is a brief summary of what was covered during this conference.
John Liddicoat, Jeffrey M Skopek, and Kathleen Liddell
On 7 and 8 April 2016, the Centre for Medical Ethics & Law (University of Hong Kong) together with the Centre for Law, Medicine and Life Sciences (University of Cambridge) hosted a conference at the University of Hong Kong on the legal and ethical challenges facing the realisation of precision medicine.
The aim of precision medicine is to revolutionise disease treatment and prevention by utilising personal variation in factors such as an individual’s genetic information, biochemistry, environment and lifestyle. Genomic data, for example, can be used to determine predispositions to particular diseases, predict the efficacy and safety of different treatment options, and help develop drugs that are targeted to the causes of diseases rather than their clinical manifestations. In these and other ways, scientific and technological advances have the potential to bring about an unprecedented tailoring of health care to the individual characteristics of patients.
In order to realise the potential of precision medicine, however, we must rethink components of the legal and ethical foundation on which it will be built. The reason for this is that our current legal and ethical frameworks were built with a very different generation of medical products and practices in mind. At this conference, world experts convened to identify and explore the challenges that precision medicine brings to the fore.
Part I of this report provides a summary of the presentations that were given at the conference. Section A of this part focuses on challenges in the implementation of precision medicine and is divided into two categories: implementation at the level of health care systems, and implementation at the level of clinical treatment. Section B addresses challenges in the development of precision medicine and is likewise divided into two categories: development at the level of foundational research, and development at the level of translational medicine.
Part II categorises and summarises the key challenges that were explored in the roundtable discussions that followed the four categories of presentations, as well as some of the broader questions that emerged out of the conference.